Clinical trials: Malignant Melanomas
Malignant Melanoma
Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28
Phase I/II clinical trial to analyze safety and efficiency of intralesional application of the bispecific single chain antibody rM28 and autologous PBMCs in patients with metastatic melanoma stage III/IV and unresectable…
- Trial name
- NCT00204594
- Testing
- rM28, autologous PBMCs
- Where
- Germany
- Volunteers
- 1 people
- Sponsor
- University Hospital Tuebingen
Thoracic Cancer, Gynecologic Cancer
Real World Study of Four PD-1 Agents in China
Consecutive patients treated with PD-1 therapy in Qingdao City were included in our study. The effecy and safety of the four PD-1 agents according to clinical outcomes in real world will be studied.
- Conditions
- Thoracic Cancer, Gynecologic Cancer, Abdomen Tumors, Malignant Melanoma
- Trial name
- NCT03966456
- Testing
- Chemotherapy
- Where
- China
- Volunteers
- 500 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Erysipelas, Impetigo
Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo
The purpose of this study is to demonstrate the validity and utility of a tele-dermatology system in the midterm periodic screening of non-widespread skin lesions of recent onset or for which a specialized early classification is…
- Conditions
- Erysipelas, Impetigo, Herpes Zoster, Molluscum Contagiosum
- Trial name
- NCT02902822
- Testing
- Screening, Tele-dermatology
- Where
- Italy
- Volunteers
- 461 people
- Sponsor
- Centro Studi Gised
Melanoma
BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation
The purpose of this phase II study is to find out if an investigational drug called LGX818 can stop the melanoma from growing.
- Trial name
- NCT01894672
- Testing
- LGX818
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Melanoma (Skin)
Pilot Study of Intervention to Reduce Sunburns in Melanoma Survivors
This project will pilot test whether a wearable device that tracks sun exposure and provides alerts regarding sun exposure and protection behaviors will reduce sunburns in melanoma survivors.
- Trial name
- NCT03518229
- Testing
- Microsoft Band 2 + UV messaging, Microsoft Band 2
- Sponsor
- University of Minnesota
Breast Cancer, Colorectal Cancer
A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors
A multicenter trial to investigate TBio-4101, an autologous, neoantigen-selected, tumor-reactive TIL product, in patients with advanced solid malignancies.
- Conditions
- Breast Cancer, Colorectal Cancer, Uveal Melanoma, Cutaneous Melanoma
- Trial name
- STARLING (NCT05576077)
- Testing
- TBio-4101, Pembrolizumab
- Where
- 13 sites in United States, Canada
- Volunteers
- 31 people
- Sponsor
- Turnstone Biologics, Corp.
Genital Tumor, Pigmented Lesions
Comparison of Dermatoscopy X400 Interpreted by 6 Non-dermatologists and an Artificial Intelligence Software Skin Artificial Intelligence Versus Dermatoscopy x 20
Pigmented lesions of the genital mucosa are common, affecting between 10% and 20% of the population. The clinical appearance is sometimes confusing.
- Trial name
- NCT06079619
- Testing
- Analysis of photos of pigmented tumours by the three groups
- Where
- France
- Volunteers
- 157 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Breast Cancer, Ovarian Cancer
Dermatological Effects and Quality of Life in Oncology Patients
This is a monocentric, low-risk interventional study designed to characterize established treatment-related dermatologic toxicity in patients receiving systemic anticancer therapies.
- Conditions
- Breast Cancer, Ovarian Cancer, NSCLC (Non-small Cell Lung Cancer), Melanoma (Skin Cancer)
- Trial name
- ReGenera (NCT07869186)
- Testing
- skin barrier assessment
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- European Institute of Oncology
Melanoma Stage III, Melanoma Stage IV
Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (stage IIIB/C/D-IV M1a) Melanoma with Injectable Disease
Currently, standard treatment options available for Stage III melanoma include locoregional management (i.e. surgery) or systemic treatment (adjuvant to surgery or primarily in the case of unresectable disease).
- Trial name
- NIVEC (NCT04330430)
- Testing
- T-VEC
- Where
- Netherlands
- Volunteers
- 24 people
- Sponsor
- The Netherlands Cancer Institute
Melanoma, Liver Metastasis
Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver
The goal of this clinical research is to find the highest tolerable dose of Abraxane (nab-paclitaxel) when given directly to the area where the cancer is located. The safety of this drug will also be studied.
- Trial name
- NCT00833807
- Testing
- Nab-Paclitaxel (Abraxane)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Malignant Melanoma
Co-stimulatory Markers and Vitamin D Status in Anti-PD1 Treated Melanoma Patients
An observational single center study designed to identify response-related biomarkers of anti-programmed death 1 (PD-1) therapy to advanced melanoma patients and to investigate if vitamin D levels are related to treatment…
- Trial name
- NCT03197636
- Testing
- Pembrolizumab
- Where
- Denmark
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Aarhus University Hospital
Melanoma
Exercise and Nutritional Intervention in Patients With Melanoma Receiving Immunotherapy
The purpose of this randomized study is to evaluate whether a six-month program of structured resistance exercise combined with individualized nutritional support can preserve or improve skeletal muscle mass and muscle quality in…
- Trial name
- MEL-FIT-IO (NCT07761871)
- Testing
- Structured Resistance Exercise, Individualized Nutritional Support
- Where
- Slovenia
- Volunteers
- 40 people
- Sponsor
- Institute of Oncology Ljubljana
Locally Advanced Unresectable or Metastatic Melanoma
Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
Approximately 40 participants with locally advanced or metastatic melanoma will be enrolled in 20 sites in the United States into 1 of the following 2 arms: Primary resistance to initial checkpoint inhibitor (CPI) therapy in Arm…
- Trial name
- NCT04768881
- Testing
- Selinexor, Pembrolizumab
- Where
- 13 sites in United States
- Volunteers
- 15 people
- Sponsor
- Karyopharm Therapeutics Inc
Unresectable Stage III or IV Malignant Melanoma
Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)
The purpose of this study is to identify candidate markers predictive of response and/or serious toxicity to BMS-734016 (MDX-010).
- Trial name
- NCT00261365
- Testing
- Ipilimumab
- Where
- 15 sites in United States, Denmark and 5 more
- Volunteers
- 80 people
- Sponsor
- Bristol-Myers Squibb
NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer)
A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.
This is a multicenter, open-label, randomized (1:1) trial designed to evaluate whether ctDNA-guided interruption of immune-checkpoint inhibitor (ICI) therapy provides comparable survival to standard of care (SoC) continuous ICI…
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Carcinoma), NSCLC
- Trial name
- SIGNAL-IO 301 (NCT07689812)
- Testing
- Signatera Genome ultra-sensitive ctDNA blood test
- Volunteers
- 920 people
- Sponsor
- Natera, Inc.
Malignant Melanoma, Cancer
Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies
The purpose of this study is to characterize the pharmacokinetics (PK) of a single intravenous (IV) infusion of 14C-labeled vemurafenib administered shortly after an oral dose of vemurafenib and following multiple oral doses of…
- Trial name
- NCT02441465
- Testing
- Vemurafenib, 14C-Labeled Vemurafenib
- Where
- Hungary
- Volunteers
- 6 people
- Sponsor
- Hoffmann-La Roche
Metastatic Cancer, Soft Tissue Sarcoma
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
This is a Phase I/IIa, multicenter, open-label, consecutive cohorts, dose-escalation study of BT-001 with repeated IT administrations alone and in combination with IV infusions of pembrolizumab.
- Conditions
- Metastatic Cancer, Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma
- Trial name
- NCT04725331
- Testing
- BT-001, Pembrolizumab [KEYTRUDA®]
- Where
- 5 sites in Belgium, France
- Volunteers
- 31 people
- Sponsor
- Transgene
Melanoma Stage III, Melanoma Stage IV
Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis
The goal of this clinical trial is to compare the safety and effectiveness of infliximab compared to steroids for the treatment of immune checkpoint inhibitor-induced colitis (ICI colitis) in patients with stage III/IV skin…
- Conditions
- Melanoma Stage III, Melanoma Stage IV, Skin Cancer Stage III, Skin Cancer Stage IV
- Trial name
- NCT04305145
- Testing
- Infliximab, Methylprednisolone, Prednisone
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Massachusetts General Hospital
Carcinoma, Non-Small-Cell Lung, Melanoma
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
This is a phase I/Ib, open label study. The escalation portion will characterize the safety and tolerability of DKY709 and DKY709 in combination with PDR001 in subjects with NSCLC or melanoma who have received prior…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Melanoma, Nasopharyngeal Carcinoma, Microsatellite Stable Colorectal Cancer
- Trial name
- NCT03891953
- Testing
- DKY709, PDR001
- Where
- 9 sites in United States, Germany and 4 more
- Volunteers
- 98 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma
A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients
This is a Open label, two-arm, randomized, two agent, single center trial.
- Trial name
- NCT01984255
- Testing
- Arm A-Bavituximab 3mg/kg IV over 90 minutes weekly x 3 followed by Bavituximab 3mg/kg IV over 90 minutes weekly x 12 plus ipilimumab 3mg/kg IV, Arm B-Ipilimumab 3mg/kg IV over 90 minutes day 1 followed three weeks later by ipilimumab every 3 weeks x 3.
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Texas Southwestern Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.